The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: ##STR00001## wherein R.sup.1 is a hydrogen atom or a hydroxyalkyl group; one of Q and T is a group represented by the general formula; ##STR00002## the other is an optionally substituted alkyl group or a cycloalkyl group; and R.sup.2 is a halogen atom, a hydroxy group, an optionally substituted alkyl group, an optionally substituted alkoxy group, an alkylthio group, a group of the general formula: -A-R.sup.3 wherein A is a single bond, an oxygen atom, a methylene group, an ethylene group, --OCH.sub.2-- or --CH.sub.2O--; and R.sup.3 is a cycloalkyl group, a heterocycloalkyl group, an optionally substituted aryl group, an optionally substituted tiazolyl group or an optionally substituted pyridyl group, pharmaceutically acceptable salts thereof or prodrugs thereof, which exert an excellent inhibitory activity in human SGLT1, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, pharmaceutical compositions comprising the same, pharmaceutical uses thereof and production intermediates thereof.